Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | YAP1 | P46937 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865997 | 0.94 | GPR119 (0.42) | GPR119DPP4DPP8DPP9DPP7 | |
| SCHEMBL865662 | 0.94 | GPR119 (0.42) | GPR119DPP4DPP8DPP9DPP7 | |
| SCHEMBL865661 | 0.94 | GPR119 (0.42) | GPR119DPP4DPP8DPP9DPP7 | |
| SCHEMBL1720527 | 0.94 | GPR119 (0.41) | GPR119DPP4DPP8DPP9DPP7 | |
| SCHEMBL865847 | 0.93 | GPR119 (0.45) | GPR119ALDH1A1LMNACHEK2YAP1 | |
| SCHEMBL865848 | 0.93 | GPR119 (0.45) | GPR119ALDH1A1LMNACHEK2YAP1 | |
| SCHEMBL864496 | 0.92 | GPR119 (0.56) | GPR119 | |
| SCHEMBL864497 | 0.92 | GPR119 (0.56) | GPR119 | |
| SCHEMBL864498 | 0.92 | GPR119 (0.56) | GPR119 | |
| SCHEMBL865760 | 0.90 | GPR119 (0.41) | GPR119DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | GPR119 1/4885DPP4 217/4885DPP8 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.